Amylin and Biocon to Partner on Diabetes Drug
Fri, 09/11/2009 - 5:00am
NEW YORK (AP) — Amylin Pharmaceuticals Inc. said Thursday it will partner with Biocon Ltd. of India to develop and market a biotech diabetes drug. Terms of the collaboration were not disclosed. The companies said they will share development costs. Amylin, of San Diego, will provide technology that can combine two hormones into one drug, while Biocon will manufacture the product and provide experience in developing diabetes treatments.